Constipation is an unsatisfactory defecation distinguished by difficult stool passage, infrequent stools or both.
Difficult stool passage may include straining, feeling of difficulty in passing stool, incomplete evacuation, lumpy/hard stools, prolonged time to defecate, need for manual maneuver to pass stool, abdominal discomfort and feeling of anorectal blockade.
Chronic constipation is considered when symptoms of constipation have existed ≥3 months.
Symptoms of chronic constipation may be due to dysfunction of intestinal motility, visceral sensitivity, anorectal musculature or the enteric nervous system.
The novel local-acting ileal bile acid transporter inhibitor elobixibat helps relieve chronic constipation in the short term, with well tolerated safety profile in the long term — supporting the novel approach of increasing intracolonic bile acid concentration for treating chronic constipation, two phase III studies show.
Depression appears to be a stronger predictor of absenteeism than symptom severity in patients with chronic constipation, suggests a study, adding that depression may partly contribute to the indirect costs of chronic constipation.
Use of plecanatide in the treatment of chronic idiopathic constipation appears to induce notable improvements in bowel movement frequency, stool consistency, and straining and abdominal symptoms, with a low incidence of adverse events, according to the results of a phase III trial.
Absenteeism among patients with chronic constipation appear to have a stronger association with depression than symptom severity, according to a recent study, suggesting that a portion of the indirect costs of chronic constipation is attributable to depression.
Prucalopride elicits more high amplitude propagating contractions compared with PEG3350 in the 12-hour period following treatment among patients with chronic constipation, a randomised, cross-over, reader-blinded study has shown.
Rebamipide reduces atypical gastrointestinal (GI) symptoms, including gastroesophageal reflux, gastroparesis, peptic ulcer, and constipation, in patients with type 2 diabetes mellitus (T2DM), according to an investigator-initiated clinical trial.
Use of potassium citrate and thiazides appears to improve health-related quality of life (HRQOL) among stone formers across all Wisconsin Stone Quality of Life (WISQOL) domains without increasing the likelihood of gastrointestinal complaints and fatigue or sexual complaints, respectively, reports a study.
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Eating high amounts of red and processed meat prior to a diagnosis of colorectal cancer appears to be associated with shorter survival time, although a possible weak association cannot be excluded, a study has shown.